Literature DB >> 6801917

Cerebrospinal fluid and acoustic neurinoma specific proteins in perilymph.

T Palva, V Raunio.   

Abstract

White rabbits were immunized with pooled and concentrated cerebro-spinal fluid (CSF) and with tumour homogenate concentrate from specimens taken from five patients with acoustic neurinoma. The absorbed anti-CSF-antitumour antiserum was tested with the micro-immunodiffusion test against normal human serum (NHS), CSF, perilymph and CSF from tumour patients and tumour homogenate. NHS showed no precipitates in any of the tests. One protein band was observed in all the other four reactants. Tumour tissue and perilymph had two proteins in common. Diffusion from the CSF space into the perilymph can thus occur via both the cochlear aqueduct and the internal acoustic meatus.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6801917     DOI: 10.3109/00016488209130872

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  9 in total

1.  Increased signal intensity of the cochlea on pre- and post-contrast enhanced 3D-FLAIR in patients with vestibular schwannoma.

Authors:  Masahiro Yamazaki; Shinji Naganawa; Hisashi Kawai; Takashi Nihashi; Hiroshi Fukatsu; Tsutomu Nakashima
Journal:  Neuroradiology       Date:  2009-12       Impact factor: 2.804

2.  Signal intensity change of the labyrinth in patients with surgically confirmed or radiologically diagnosed vestibular schwannoma on isotropic 3D fluid-attenuated inversion recovery MR imaging at 3 T.

Authors:  In Ho Lee; Hyung-Jin Kim; Won Ho Chung; Eunhee Kim; Jung Won Moon; Sung Tae Kim; Keon Ha Kim; Pyoung Jeon; Hong Sik Byun
Journal:  Eur Radiol       Date:  2009-11-07       Impact factor: 5.315

3.  MRI of endolymphatic hydrops in patients with vestibular schwannomas: a case-controlled study using non-enhanced T2-weighted images at 3 Teslas.

Authors:  Aurélie Karch-Georges; Francis Veillon; Hella Vuong; Dominique Rohmer; Anne Karol; Anne Charpiot; Nicolas Meyer; Aina Venkatasamy
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-03-27       Impact factor: 2.503

4.  Relationship between Signal Intensity of the Labyrinth and Cochleovestibular Testing and Morphologic Features of Vestibular Schwannoma.

Authors:  Felipe Constanzo; Bernardo Corrêa de Almeida Teixeira; Patricia Sens; Dante Escuissato; Ricardo Ramina
Journal:  J Neurol Surg B Skull Base       Date:  2021-03-08

5.  Clinical significance of an increased cochlear 3D fluid-attenuated inversion recovery signal intensity on an MR imaging examination in patients with acoustic neuroma.

Authors:  D Y Kim; J H Lee; M J Goh; Y S Sung; Y J Choi; R G Yoon; S H Cho; J H Ahn; H J Park; J H Baek
Journal:  AJNR Am J Neuroradiol       Date:  2014-04-17       Impact factor: 3.825

6.  Increased cochlear fluid-attenuated inversion recovery signal in patients with vestibular schwannoma.

Authors:  R A Bhadelia; K L Tedesco; S Hwang; S H Erbay; P H Lee; W Shao; C Heilman
Journal:  AJNR Am J Neuroradiol       Date:  2008-01-31       Impact factor: 3.825

7.  Differentiation of vestibular schwannomas from meningiomas of the internal auditory canal using perilymphatic signal evaluation on T2-weighted gradient-echo fast imaging employing steady state acquisition at 3T.

Authors:  A Venkatasamy; D Le Foll; A Karol; B Lhermitte; A Charpiot; C Debry; F Proust; N Meyer; F Veillon
Journal:  Eur Radiol Exp       Date:  2017-06-29

8.  Current Understanding of Hearing Loss in Sporadic Vestibular Schwannomas: A Systematic Review.

Authors:  Jinlu Gan; Yanling Zhang; Jingnan Wu; Deqiang Lei; Fangcheng Zhang; Hongyang Zhao; Lei Wang
Journal:  Front Oncol       Date:  2021-08-12       Impact factor: 6.244

Review 9.  Biomarkers in Vestibular Schwannoma-Associated Hearing Loss.

Authors:  Luis Lassaletta; Miryam Calvino; Jose Manuel Morales-Puebla; Pablo Lapunzina; Lourdes Rodriguez-de la Rosa; Isabel Varela-Nieto; Victor Martinez-Glez
Journal:  Front Neurol       Date:  2019-09-18       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.